以结构为基础的设计和在中评估一个脂性环氧甲乙烯衍生物作为宁抑制剂:从撤回的阿利斯基伦中吸取的教训
Dimitrios Pavlos1, Errikos Petsas1, Filippos Panteleimon Chatzipieris1
1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.
International journal of molecular sciences
|December 11, 2025
概括
一个新的计算设计产生了N-CDAH,这是一个有前途的宁抑制剂支架. 它显示出比阿利斯基伦更好的特性,提供了潜在的新型高血压治疗方法,并提高了安全性和有效性.
科学领域:
- 药用化学 医学化学
- 计算机化药物设计技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸是氨酸- ангиотензин- алдостерон系统 (RAAS) 中高血压治疗的关键标.
- 由于安全问题和药物相互作用,唯一批准的直接宁抑制剂Aliskiren被撤回.
- 需要新的,更安全的宁抑制剂.
研究的目的:
- 通过计算设计和评估一种新型支架,N-CDAH,作为下一代直接宁抑制剂.
- 与阿利斯基伦相比,评估N-CDAH的药理动力学,ADME和毒性概况.
- 为了研究N-CDAH在蛋白活性部位内的结合相互作用和稳定性.
主要方法:
- 计算式蛋白质设计被用来创建N-CDAH支架,优化脂友性和代谢稳定性.
- 使用瑞士ADME和pkCSM进行了药理动力学,ADME和毒性预测.
- 用分子对接和分子动力学模拟来评估结合亲和力和复杂稳定性.
主要成果:
- 与阿利斯基伦相比,N-CDAH表现出预测的优异水溶性,增强的代谢稳定性和减少的目标外负债.
- 分子对接显示出强大的结合亲和力 (-8.08 kcal/mol) 和在蛋白活性部位内的有利相互作用.
- 分子动力学模拟证实了通过疏水性封闭和离子相互作用的稳定结合,没有主要CYP异型的抑制.
结论:
- N-CDAH代表了下一代宁抑制剂的有希望的支架,可能克服阿利斯基伦的局限性.
- 整合性在的结果为N-CDAH的实验验证提供了强有力的理由.
- 基于结构的药物设计对于开发新型抗高血压疗法至关重要.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:28Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
01:28Renal Drug Excretion: Tubular Secretion
738
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
738
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K